TORM PTO-1449 (REV. 7-85)

AT

/Deepak Rao/

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENTAND TRADEMARK OFFICE

INFORMATION DISCLEDIA

URE CITATION

(Use several sheets if necessary)

JC14 Rec'd PCT/PTO 23 MAR 2005

-Herewith- 01/05/2006

ATTY. DOCKET NO ON/4-32 APPLICA NO. Notyetassigned-APPLICANT MANLEY ET AL. FILING DATE 10/528913

Group 1624

U.S. PATENT DOCUMENTS EXAMINER **DOCUMENT NUMBER** DATE **FILING DATE** NAME CLASS **SUBCLASS** INITIAL AA AB AC AD AE AF AG AH ΑI AJ AK AL **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO **DOCUMENT NUMBER** DATE CLASS SUBCLASS **OFFICE** /DR/ AM 02 22597A 3/21/02 WO AN 0 564 409A 10/6/93 WO /DR/ /DR/ AO 02 93164 wo 11/21/02 AP AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) **AR** AS

DATE CONSIDERED

10/01/2007

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets If necessary)

ATTY. DOCKET NO. ON/4-32700A APPLICATION NO. 10/528,913 APPLICANT MANLEY ET AL. FILING DATE JANUARY 5, 2006

Group 1624

APR 1 1 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/DR/	AA	5,215,989	06/01/93	Baldwin et al.			
/DR/	AB	5,521,184	05/28/96	Zimmermann			
/DR/	AC	5,516,775	05/14/96	Zimmermann et al.			
	AD						
	AE						
	AF						
	AG						
	АН						
	Αl						77.
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	IRAN YES	SLATION NO
/DR/	/ AN	EP 0 233 461	08/26/87	Europe				
	AN	EP 0 564 409	10/06/93	Europe [English equiv. Is US 5,521,184]				
	AC	EP 0 588 762	03/23/94	Europe (English equiv. is US 5,516,775)				
	AF	GB 2 369 359	05/29/02	UK			-0	
$-\mathbf{V}$	AC	WO 95/09847	04/13/95	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/DR/	AR	Buchdunger et al., "Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class", <i>Proc Natl Acad Sci USA</i> , Vol. 92, No. 7, pp. 2558-2562 (1995).
/DR/	AS	Buchdunger et al., "Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative", Cancer Res, Vol. 56, No. 1, pp. 100-104 (1996).
/DR/	АТ	Carroll et al., "CGP 57148, A Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins", <i>Blood</i> , Vol. 90, No. 12, pp. 4947–4952 (1997).

/Deepak Rao/ Date Considered 10/01/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32700A APPLICATION NO. 10/528,913 APPLICANT MANLEY ET AL. FILING DATE **JANUARY 5, 2006**

Group 1624

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
/DR/	CA	WO 95/09852	04/13/95	WIPO				
	СВ	WO 01/47507	07/05/01	WIPO			- 🗆	
	СС	WO 01/64200	09/07/01	WIPO				
	CD	WO 02/22597	03/31/02	WIPO				
$\overline{\mathbf{A}}$	CE	WO 02/093164	11/21/02	WIPO				
	CF							
	CG							
	СН							
	CI							
	CJ							
	СК							
	CL							
	СМ							
-	CN							
	СО							
	СР							
	ca							
	CR							
	cs							
	СТ							
	cu							
	cv							
	cw							
	СХ							
	CY							
EXAMIN	CZ			DATE CONCIDENCE				
		/Deepak Rao/		DATE CONSIDERED	0/01/2007			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32700A APPLICATION NO. 10/528,913 APPLICANT MANLEY ET AL. FILING DATE JANUARY 5, 2006

Group 1624

EXAMINER	ОТН	ER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
/DR/	DA	Druker et al., "Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells", <i>Nat Med</i> , Vol. 2, No. 5, pp. 561-566 (1996).
/DR/	DB	Druker et al., "Selective Killing of Bcr-Abl Positive Cells with a Specific Inhibitor of the Abl Tyrosine Kinase", Pezcoller Foundation Symposia, Cancer Genes, pp. 255-267 (1996).
/DR/	DC	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)", <i>Arch Pharm Pharm Med Chem</i> , Vol. 329, No. 7, pp. 371-376 (1996).
/DR/	DD	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) – Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors", <i>Bioorg Med Chem Lett</i> , Vol. 6, No. 11, pp. 1221-1226 (1996).
/DR/	DE	Zimmermann et al., "Potent and Selective Inhibitors of the Abl-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives", <i>Bioorg Med Chem Lett</i> , Vol. 7, No. 2, pp. 187-192 (1997).
	DF	
	DG	·
	DH	·
	DI	
	DJ	
	DK	· ·
	DL	
	DM	
	DN	
EXAMINE	R	/Deepak Rao/ DATE CONSIDERED 10/01/2007

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.